President Trump announced a phased tariff plan that will impose steep duties on imported generic drugs starting in 2028, aiming to encourage domestic production of generics.
Impact: The news is likely to weigh on U.S. pharmaceutical companies that rely on generic drug sales, creating short‑term stock pressure.
Not investment advice